224 related articles for article (PubMed ID: 2293559)
1. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
Fram RJ; Woda BA; Wilson JM; Robichaud N
Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
[TBL] [Abstract][Full Text] [Related]
2. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
3. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
4. Quenching of DNA:platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells.
Micetich K; Zwelling LA; Kohn KW
Cancer Res; 1983 Aug; 43(8):3609-13. PubMed ID: 6683124
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells.
Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB
Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621
[TBL] [Abstract][Full Text] [Related]
7. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
Masuda H; Tanaka T; Matsuda H; Kusaba I
Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
[TBL] [Abstract][Full Text] [Related]
8. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
[TBL] [Abstract][Full Text] [Related]
9. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
10. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
Frühauf S; Zeller WJ
Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of DNA cross-linking in normal and neoplastic mouse tissues following treatment with cis-diamminedichloroplatinum(II) in vivo.
Murray D; Jenkins WT; Meyn RE
Cancer Res; 1985 Dec; 45(12 Pt 1):6446-52. PubMed ID: 4063992
[TBL] [Abstract][Full Text] [Related]
12. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
Aida T; Bodell WJ
Cancer Res; 1987 Mar; 47(5):1361-6. PubMed ID: 3469016
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
14. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
[TBL] [Abstract][Full Text] [Related]
15. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.
Richon VM; Schulte N; Eastman A
Cancer Res; 1987 Apr; 47(8):2056-61. PubMed ID: 3828995
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).
Teicher BA; Holden SA; Kelley MJ; Shea TC; Cucchi CA; Rosowsky A; Henner WD; Frei E
Cancer Res; 1987 Jan; 47(2):388-93. PubMed ID: 3539321
[TBL] [Abstract][Full Text] [Related]
17. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
19. The formation of DNA interstrand cross-links by a novel bis-[Pt2Cl4(diminazene aceturate)2]Cl4.4H2O complex inhibits the B to Z transition.
González VM; Fuertes MA; Jiménez-Ruíz A; Alonso C; Pérez JM
Mol Pharmacol; 1999 Apr; 55(4):770-7. PubMed ID: 10101036
[TBL] [Abstract][Full Text] [Related]
20. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking.
Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC
Cancer Res; 1989 Mar; 49(6):1383-9. PubMed ID: 2924295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
